For example, E2F7 was upregulated in bladder urothelial carcinoma, breast cancer, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, glioblastoma, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, LUAD, lung squamous cell carcinoma, rectum adenocarcinoma (P < .001). Here, E2F7 is linked to bladder transitional cell carcinoma.